

- ILUVIEN[®] (0.2 µg/day fluocinolone acetonide [FAC]) is indicated for the treatment of vision impairment associated with chronic diabetic macular edema (DME), considered insufficiently responsive to available therapies.
- There are limited data in patients with bilateral chronic DME. Herein, the visual and anatomical results are presented from six pseudophakic patients with bilateral, chronic DME previously treated with laser and anti-VEGF therapy.
- 6-months post-0.2 µg/day FAC implant in both eyes, best-corrected visual acuity improved by an average of 10-letters from 43 Early Treatment Diabetic Retinopathy Study letters; mean central retinal thickness decreased by a mean of 282 µm from a baseline value of 648 µm; and, mean intraocular pressure was 16.1 mmHg.
- In a real-world setting, 0.2 µg/day FAC implant in both eyes was a feasible, effective choice for patients with severe bilateral DME, without notable increases in IOP.

This summary slide represents the opinions of the authors. Publication charges for this study were funded by Alimera Sciences Ltd. Medical writing assistance for this study was provided by QXV Communications and funded by Alimera Sciences Ltd. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2016. Creative Commons Attribution Noncommercial License (CC BY-NC).